Injectable biostimulators under the microscope: a safety deep dive

NCT ID NCT06993558

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial investigates the safety and tissue effects of two injectable biostimulators—Poly-L-Lactic Acid (PLLA) and Calcium Hydroxyapatite (CaHA)—used for facial rejuvenation in healthy volunteers aged 30 and older. Participants receive one or two treatment sessions, followed by four check-ups to monitor inflammation, deposit formation, and tissue changes using ultrasound. The goal is to better understand how these treatments interact with facial tissues and their safety profile.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Poly-L-Lactic Acid (PLLA) or Calcium Hydroxyapatite (CaHA) injections
What this could lead to
If successful, this could confirm the safety of these injectable biostimulators for cosmetic facial rejuvenation.
What could go wrong
This is a small, early-phase study in healthy volunteers, so results may not apply to broader populations or reveal rare side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THIS STUDY AIMS TO EVALUATE THE SAFETY PROFILE AND TISSUE CHANGES AFTER BIOSTIMULATORY TREATMENTS TO THE FACE IN HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Hamburg Eppendorf

    RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••